Inducing efficient cross-priming using antigen-coated yeast particles

Journal of Immunotherapy

Volumn 31, Issue 7, 2008, Pages 607-619

  Howland, Shanshan W ^a   Tsuji, Takemasa ^b   Gnjatic, Sacha ^b   Ritter, Gerd ^b   Old, Lloyd J ^b   Wittrup, Karl Dane ^c,d  

^a Departments of Biological Engineering   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer vaccine; Conjugation; Cross presentation; Cross priming; Yeast

Indexed keywords

AMINE; CATHEPSIN S; CD74 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; LYMPHOCYTE ANTIGEN; NY ESO 1 ANTIGEN; PANTETHEINE PHOSPHATE; PROTEIN SNAP TAG; TRANSFERASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; B LYMPHOCYTE ANTIGEN; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; HLA ANTIGEN CLASS 2; HYBRID PROTEIN; MATRIX PROTEIN; MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE FRAGMENT; PHOSPHOPROTEIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL WALL; COATED PARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CONJUGATION; DRUG POTENCY; DRUG RELEASE; FUNGAL STRAIN; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOREACTIVITY; IN VITRO STUDY; INTERFERON PRODUCTION; NONHUMAN; PHAGOSOME; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; YEAST CELL; AMINATION; CELL DIFFERENTIATION; CHEMISTRY; COATED VESICLE; CYTOMEGALOVIRUS; ESCHERICHIA COLI; GENETICS; IMMUNOLOGY; INVARIANT CHAIN; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MICROBIOLOGY; PROTEIN TRANSPORT; SECRETION; TESTIS TUMOR;

AMINATION; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; COATED VESICLES; CROSS-PRIMING; CYTOMEGALOVIRUS; DENDRITIC CELLS; ESCHERICHIA COLI; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; TESTICULAR NEOPLASMS; VIRAL MATRIX PROTEINS;

EID: 63849220345     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318181c87f     Document Type: Article

References (46)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
2. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488-496.
3. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001;7:625-629.
4. Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004;64:5084-5088.
5. Franzusoff A, Duke RC, King TH, et al. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opinion Biol Ther. 2005; 5:565-575.
6. Barron MA, Blyveis N, Pan SC, et al. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol. 2006;26:251-264.
7. Haller AA, Lauer GM, King TH, et al. Whole recombinant yeastbased immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25:1452-1463.
8. Riemann H, Takao J, Shellman YG, et al. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol. 2007;16:814-822.
9. Bernstein MB, Chakraborty M, Wansley EK, et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine. 2008;26:509-521.
10. Munson S, Parker J, King TH, et al. Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. In: Orentas R, Hodge JW, Johnson BD, eds. Cancer Vaccines and Tumor Immunity. New York: Wiley-Liss; 2008:131-149.
11. Wadle A, Held G, Neumann F, et al. Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine. 2006;24:6272-6281.
12. Howland SW, Wittrup KD. Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol. 2008;180:1576-1583.
13. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553-557.
14. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
15. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NYESO- 1. Immunol Cell Biol. 2006;84:303-317.
16. Piatesi A, Howland SW, Rakestraw JA, et al. Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast. Protein Exp Purif. 2006;48:232-242.
17. Chao G, Lau WL, Hackel BJ, et al. Isolating and engineering human antibodies using yeast surface display. Nat Protoc. 2006;1: 755-768.
18. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics. 1989;122:19-27.
19. Yin J, Lin AJ, Golan DE, et al. Site-specific protein labeling by Sfp phosphopantetheinyl transferase. Nat Protoc. 2006;1:280-285.
20. Reichelt P, Schwarz C, Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Exp Purif. 2006;46:483-488.
21. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci. 2000;97:10917-10922.
22. Ho WY, Nguyen HN, Wolfl M, et al. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods. 2006;310:40-52.
23. Keppler A, Kindermann M, Gendreizig S, et al. Labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase with small molecules in vivo and in vitro. Methods. 2004;32:437-444.
24. Ruckrich T, Brandenburg J, Cansier A, et al. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biol Chem. 2006;387: 1503-1511.
25. Riese RJ, Wolf PR, Bromme D, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996;4:357-366.
26. Chen J-L, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumorreactive CTL. J Immunol. 2000;165:948-955.
27. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cellmediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995;80:695-705.
28. Kersh G, Allen P. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med. 1996;184:1259-1268.
29. Hemmer B, Vergelli M, Gran B, et al. Cutting edge: predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol. 1998;160:3631-3636.
30. Hemmer B, Vergelli M, Pinilla C, et al. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today. 1998;19:163-168.
31. Misko IS, Cross SM, Khanna R, et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci. 1999;96: 2279-2284.
32. Chen J, Eisen HN, Kranz DM. A model T-cell receptor system for studying memory T-cell development. Microbes Infect. 2003;5: 233-240.
33. Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol. 2004;40:1009-1017.
34. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today. 1998;19:395-404.
35. Murphy R, Green S, Ritter G, et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep Biochem Biotechnol. 2005;35:119-134.
36. Edwards AD, Manickasingham SP, Sporri R, et al. Microbial recognition via toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol. 2002;169:3652-3660.
37. Dillon S, Agrawal S, Banerjee K, et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest. 2006;116:916-928.
38. Bohnenkamp HR, Papazisis KT, Burchell JM, et al. Synergism of toll-like receptor-induced interleukin-12p70 secretion by monocytederived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type I responses. Cell Immunol. 2007; 247:72-84.
39. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol. 2002;169:6842-6849.
40. Chang J, Cho J-H, Lee S-W, et al. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol. 2004; 172:2818-2826.
41. DI' az-Montero C, El Naggar S, Al Khami A, et al. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol, Immunother. 2008;57:563-572.
42. Wickner RB. Prions and RNA viruses of Saccharomyces cerevisiae. Annu Rev Genet. 1996;30:109-139.
43. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathogens. 2006;2:e35.
44. Falo LD, Kovacsovics-Bankowski M, Thompson K, et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med. 1995;1:649-653.
45. Pozzi L-AM, Maciaszek JW, Rock KL. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol. 2005;175:2071-2081.
46. Beauvillain C, Delneste Y, Scotet M, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood. 2007;110:2965-2973.